EUVIMEDOntdek EUVIMED
Klinische Studie (Phase II)Randomisierte kontrollierte StudieOpen access · CC BY-NC 4.0

The effect of M‐current activation on controller gain and obstructive sleep apnoea severity: a randomised controlled trial using flupirtine

Luke D J Thomson iD, Shane A Landry, Andre Arellano, Jinny Collet, Stuart Huddle, Denise M O'Driscoll iD, Dwayne L Mann iD, Caroline Beatty, Simon A Joosten, Garun S Hamilton, Phillip J Berger, Ian Cooke and 1 more

The Journal of Physiology · 2025

DOI: 10.1113/jp288337 ↗

At a glance

Klinische Studie (Phase II) in The Journal of Physiology, 2025. Written by Luke D J Thomson and 12 co-authors. Institution: Department of Physiology, School of Biomedical Sciences and Biomedical Discovery Institute, Monash University, Melbourne, VIC, Australia. Major MEDLINE topics: Aminopyridines, Sleep Apnea, Obstructive. Cited 2 times so far (Crossref); 44 references. The full text is freely available (open access, CC BY-NC 4.0). Funded by: Monash Research Impact Fund, Monash Lung and Sleep Institute.

SamenvattingSubjectsBibliografische gegevensCiteRelated studies

Abstract (original language)

Ventilatory control instability, or high loop gain (LG), contributes towards upper airway collapse in approximately one‐third of people with obstructive sleep apnoea (OSA). A high LG can be the product of elevated chemosensitivity (controller gain) and/or an excessive ventilatory output (plant gain). Therapies such as carbonic anhydrase inhibitors (targeting plant gain) have been shown to reduce OSA severity; however, there is a lack of viable pharmacological options targeting controller gain. This study investigated the effect of flupirtine (400 mg), a KCNQ potassium channel opener, on LG and OSA severity in fifteen moderate‐to‐severe OSA patients through a randomised, double‐blind, placebo‐controlled trial. Despite the hypothesised potential of flupirtine to reduce LG by attenuating chemosensory activity, our findings revealed no significant effect on LG and OSA severity. The lack of overall efficacy of flupirtine is most likely due to multifactorial nature of OSA and the challenges of its management. Our findings suggest a need for a nuanced understanding of OSA pathogenesis and caution against the use of flupirtine in managing OSA. While, pharmacological modulation of ionic channels within the ventilatory control system presents a promising strategy, given the plethora of robust targets available, it remains to be determined whether an effective treatment can capitalise on a single predominant ionic current ubiquitous throughout the ventilatory system, or if a more successful approach necessitates the simultaneous modulation of multiple targets. This research enhances our understanding of the ventilatory control system's contribution to OSA and the complexity of finding a one‐size‐fits‐all treatment. image Key points Around one‐third of obstructive sleep apnoea (OSA) cases involve an unstable control of breathing, leading to airway collapse. This research examined whether the drug flupirtine could stabilise breathing control and reduce OSA severity in 15 patients. Flupirtine, which was expected to improve breathing control by reducing chemosensitivity, showed no significant benefit for OSA. While targeting ionic channels in the breathing system is promising, the search for an effective OSA treatment may require addressing multiple targets simultaneously.

Subjects

MeSH terms (MEDLINE)

AminopyridinesSleep Apnea, ObstructiveAdultFemaleHumansMaleMiddle AgedDouble-Blind MethodSeverity of Illness Index

Author keywords

loop gainpotassium channel openersleep apnea pharmacotherapy

Substances

Aminopyridinesflupirtine

Authors and institutions

  • Department of Physiology, School of Biomedical Sciences and Biomedical Discovery Institute, Monash University, Melbourne, VIC, Australia.
  • School of Psychological Science, Monash University, Melbourne, VIC, Australia.
  • Department of Respiratory and Sleep Medicine, Eastern Health, Melbourne, Australia.
  • Eastern Health Clinical School, Monash University, Melbourne, VIC, Australia.
  • School of Electrical Engineering and Computer Science, The University of Queensland, Brisbane, QLD, Australia.
  • School of Clinical Sciences, Monash University, Melbourne, VIC, Australia.

ORCID profiles: Luke D J Thomson, Denise M O'Driscoll, Dwayne L Mann, Bradley A Edwards

Funding

  • Monash Research Impact Fund
  • Monash Lung and Sleep Institute

Cite

APA

Thomson, L. D. J., Landry, S. A., Arellano, A., Collet, J., Huddle, S., O'Driscoll, D. M., Mann, D. L., Beatty, C., Joosten, S. A., Hamilton, G. S., Berger, P. J., Cooke, I., & Edwards, B. A. (2025). The effect of M‐current activation on controller gain and obstructive sleep apnoea severity: a randomised controlled trial using flupirtine. The Journal of Physiology. https://doi.org/10.1113/jp288337

Vancouver

Thomson LDJ, Landry SA, Arellano A, Collet J, Huddle S, O'Driscoll DM, et al. The effect of M‐current activation on controller gain and obstructive sleep apnoea severity: a randomised controlled trial using flupirtine. The Journal of Physiology. 2025. doi:10.1113/jp288337

BibTeX
@article{Thomson2025,
  author = {Thomson, Luke D J and Landry, Shane A and Arellano, Andre and Collet, Jinny and Huddle, Stuart and O'Driscoll, Denise M and Mann, Dwayne L and Beatty, Caroline and Joosten, Simon A and Hamilton, Garun S and Berger, Phillip J and Cooke, Ian and Edwards, Bradley A},
  title = {The effect of M‐current activation on controller gain and obstructive sleep apnoea severity: a randomised controlled trial using flupirtine},
  journal = {The Journal of Physiology},
  year = {2025},
  doi = {10.1113/jp288337}
}
Start for free →